📰 ET Stocks 🏛️ RBI/POLICY 🕒 11 Sep 2026, 08:22 PM IST

NSEL settlement scheme: Sebi settles proceedings against 91 commodity brokers

⚡ Instant Key Takeaways (TL;DR)

🎯

Core Development: NSEL settlement scheme: Sebi settles proceedings against 91 commodity brokers

📊

Market & Financial Impact: Sebi has concluded its proceedings against ninety-one commodity brokers linked to the NSEL issue, allowing these firms to participate in a settlement scheme. Many brokers consented to temporary limitations on proprietary trading and onboarding new clients, with some remitting settlement fees of up to thirty-six lakh rupees. This move aligns with the directive from the Securities Appellate Tribunal regarding an orderly settlement process.

💡

Actionable Insight: 🏛️ Policy & Macro: Interest rate, inflation, or regulatory changes affecting broad market valuations.

Top Trending Stocks: SBI Share Price, Axis Bank Share Price, HDFC Bank Share Price, Infosys Share Price, Wipro Share Price, NTPC Share Price

Bigger or Better: One order from Power Grid Corp added $1 billion to the market cap of a company – Final part

Banks have received a flood of money. Now comes the real test

New aircraft order opens door for ATR assembly line in India

📰

Official Publisher Attribution: This report is aggregated from Economic Times. ZeroLive provides live aggregation, automated sentiment synthesis, and exchange disclosure monitoring for retail market participants.

Read Original Full Coverage on Economic Times ↗

NSEL settlement scheme: Sebi settles proceedings against 91 commodity brokers

🔥 More Live Market Stories

[UFBL] Giving guarantees/indemnity/ becoming a surety for third party - United Foodbrands Limited

[HINDALCO] Analysts/Institutional Investor Meet/Con. Call Updates - Hindalco Industries Limited

[JKIPL] General Updates - Jinkushal Industries Limited

Britain Just Admitted It Uses SpaceX’s Secret Military Network. The Contracts Already Top $6 Billion.

[IBULLSLTD] Updates - Indiabulls Limited

Belite Bio at Cantor healthcare conference: tinlarebant advances